Home > Publications database > Preparation, characterization and evaluation of HPβCD-PTX/PHB nanoparticles for pH-responsive, cytotoxic and apoptotic properties. > print

001     290204
005     20250814095538.0
024 7 _ |a 10.1016/j.ijbiomac.2024.132268
|2 doi
024 7 _ |a pmid:38734336
|2 pmid
024 7 _ |a 0141-8130
|2 ISSN
024 7 _ |a 1879-0003
|2 ISSN
037 _ _ |a DKFZ-2024-01037
041 _ _ |a English
082 _ _ |a 570
100 1 _ |a Aslam, Aqsa
|b 0
245 _ _ |a Preparation, characterization and evaluation of HPβCD-PTX/PHB nanoparticles for pH-responsive, cytotoxic and apoptotic properties.
260 _ _ |a New York, NY [u.a.]
|c 2024
|b Elsevier
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1734098142_9063
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a Volume 270, Part 2, June 2024, 132268
520 _ _ |a Paclitaxel (PTX) is a potent anticancer drug. However, PTX exhibits extremely poor solubility in aqueous solution along with severe side effects. Therefore, in this study, an inclusion complex was prepared between PTX and hydroxypropyl-β-cyclodextrin (HPβCD) by solvent evaporation to enhance the drug's solubility. The HPβCD-PTX inclusion complex was then encapsulated in poly-3-hydroxybutyrate (PHB) to fabricate drug-loaded nanoparticles (HPβCD-PTX/PHB NPs) by nanoprecipitation. The HPβCD-PTX/PHB NPs depicted a higher release of PTX at pH 5.5 thus demonstrating a pH-dependent release profile. The cytotoxic properties of HPβCD-PTX/PHB NPs were tested against MCF-7, MDA-MB-231 and SW-620 cell lines. The cytotoxic potential of HPβCD-PTX/PHB NPs was 2.59-fold improved in MCF-7 cells in comparison to free PTX. Additionally, the HPβCD-PTX/PHB NPs improved the antimitotic (1.68-fold) and apoptotic (8.45-fold) effects of PTX in MCF-7 cells in comparison to PTX alone. In summary, these pH-responsive nanoparticles could be prospective carriers for enhancing the cytotoxic properties of PTX for the treatment of breast cancer.
536 _ _ |a 311 - Zellbiologie und Tumorbiologie (POF4-311)
|0 G:(DE-HGF)POF4-311
|c POF4-311
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a HPβCD-drug inclusion complex
|2 Other
650 _ 7 |a Nano-system
|2 Other
650 _ 7 |a PHB
|2 Other
650 _ 7 |a Paclitaxel
|2 Other
700 1 _ |a Masood, Farha
|b 1
700 1 _ |a Perveen, Kousar
|b 2
700 1 _ |a Berger, Martin
|0 P:(DE-He78)7e60033e3eaaebb9ba30c905ade4a676
|b 3
700 1 _ |a Pervaiz, Asim
|b 4
700 1 _ |a Zepp, Michael
|0 P:(DE-He78)8da28eac875d8c53905ac3f4393784b8
|b 5
700 1 _ |a Klika, Karel D
|0 P:(DE-He78)c53db83479d3d1265967405af71f69bb
|b 6
700 1 _ |a Yasin, Tariq
|b 7
700 1 _ |a Hameed, Abdul
|b 8
773 _ _ |a 10.1016/j.ijbiomac.2024.132268
|g p. 132268 -
|0 PERI:(DE-600)1483284-7
|n Part 2
|p 132268
|t International journal of biological macromolecules
|v 270
|y 2024
|x 0141-8130
856 4 _ |u https://inrepo02.dkfz.de/record/290204/files/1-s2.0-S0141813024030733-main.pdf
856 4 _ |u https://inrepo02.dkfz.de/record/290204/files/1-s2.0-S0141813024030733-main.pdf?subformat=pdfa
|x pdfa
909 C O |p VDB
|o oai:inrepo02.dkfz.de:290204
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)7e60033e3eaaebb9ba30c905ade4a676
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)8da28eac875d8c53905ac3f4393784b8
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)c53db83479d3d1265967405af71f69bb
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-311
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Zellbiologie und Tumorbiologie
|x 0
914 1 _ |y 2024
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2023-10-21
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b INT J BIOL MACROMOL : 2022
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-10-21
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-10-21
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-10-21
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b INT J BIOL MACROMOL : 2022
|d 2023-10-21
920 1 _ |0 I:(DE-He78)G401-20160331
|k G401
|l Molekulare Toxikologie und Chemotherapie
|x 0
920 1 _ |0 I:(DE-He78)A390-20160331
|k A390
|l AG Wirkstoffforschung
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)G401-20160331
980 _ _ |a I:(DE-He78)A390-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21